JP2022526419A5 - - Google Patents
Info
- Publication number
- JP2022526419A5 JP2022526419A5 JP2021559265A JP2021559265A JP2022526419A5 JP 2022526419 A5 JP2022526419 A5 JP 2022526419A5 JP 2021559265 A JP2021559265 A JP 2021559265A JP 2021559265 A JP2021559265 A JP 2021559265A JP 2022526419 A5 JP2022526419 A5 JP 2022526419A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962829595P | 2019-04-04 | 2019-04-04 | |
| US62/829,595 | 2019-04-04 | ||
| PCT/US2020/026717 WO2020206350A1 (en) | 2019-04-04 | 2020-04-03 | Compositions and methods for inhibiting gene expression in the central nervous system |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022526419A JP2022526419A (ja) | 2022-05-24 |
| JPWO2020206350A5 JPWO2020206350A5 (https=) | 2023-07-11 |
| JP2022526419A5 true JP2022526419A5 (https=) | 2023-07-11 |
Family
ID=70482804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559265A Abandoned JP2022526419A (ja) | 2019-04-04 | 2020-04-03 | 中枢神経系における遺伝子発現を阻害するための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220170025A1 (https=) |
| EP (1) | EP3947683A1 (https=) |
| JP (1) | JP2022526419A (https=) |
| KR (1) | KR20210148264A (https=) |
| CN (1) | CN113748208A (https=) |
| AU (1) | AU2020252560A1 (https=) |
| BR (1) | BR112021019793A2 (https=) |
| CA (1) | CA3135402A1 (https=) |
| CL (1) | CL2021002585A1 (https=) |
| IL (1) | IL286868A (https=) |
| MX (1) | MX2021012126A (https=) |
| SG (1) | SG11202110896WA (https=) |
| WO (1) | WO2020206350A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019143621A1 (en) | 2018-01-16 | 2019-07-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting aldh2 expression |
| CN119499394A (zh) | 2019-11-01 | 2025-02-25 | 阿尔尼拉姆医药品有限公司 | 亨廷顿（HTT）iRNA药剂组合物及其使用方法 |
| EP4073251A1 (en) | 2019-12-13 | 2022-10-19 | Alnylam Pharmaceuticals, Inc. | Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof |
| EP4244356A1 (en) * | 2020-11-13 | 2023-09-20 | Dicerna Pharmaceuticals, Inc. | Chemical modifications for inhibiting expression of aldh2 |
| AR124713A1 (es) * | 2021-01-28 | 2023-04-26 | Dicerna Pharmaceuticals Inc | Composiciones y métodos para inhibir la expresión de genes en el sistema nervioso central |
| WO2022174000A2 (en) | 2021-02-12 | 2022-08-18 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
| CN117222739A (zh) | 2021-02-25 | 2023-12-12 | 阿尔尼拉姆医药品有限公司 | 朊病毒蛋白(prnp)irna组合物和其使用方法 |
| WO2022192519A1 (en) | 2021-03-12 | 2022-09-15 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
| WO2022212231A2 (en) | 2021-03-29 | 2022-10-06 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt) irna agent compositions and methods of use thereof |
| PE20250074A1 (es) * | 2021-05-28 | 2025-01-13 | Novo Nordisk As | Composiciones y metodos para inhibir la expresion del componente 1 de reduccion de amidoxima mitocondrial (marc1) |
| CN117561334A (zh) | 2021-06-04 | 2024-02-13 | 阿尔尼拉姆医药品有限公司 | 人染色体9开放阅读框72（C9ORF72）iRNA药剂组合物和其使用方法 |
| JP2024532019A (ja) * | 2021-08-25 | 2024-09-05 | ノボ ノルディスク エー／エス | アルファ－１アンチトリプシン発現を阻害するための組成物及び方法 |
| WO2023076450A2 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
| AR127587A1 (es) * | 2021-11-05 | 2024-02-07 | Dicerna Pharmaceuticals Inc | Conjugación de lípidos para dirigir oligodendrocitos del sistema nervioso central |
| TW202335674A (zh) * | 2021-11-05 | 2023-09-16 | 美商黛瑟納製藥公司 | 靶定中樞神經系統的星狀細胞之脂質結合物 |
| WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
| CN119173631A (zh) * | 2022-05-12 | 2024-12-20 | 迪克纳制药公司 | 用于抑制mapt表达的组合物和方法 |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1309726E (pt) | 2000-03-30 | 2010-03-08 | Whitehead Biomedical Inst | Mediadores de interferência por rna específicos de sequência de rna |
| US20040259247A1 (en) | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20050159378A1 (en) | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| US20050019915A1 (en) * | 2001-06-21 | 2005-01-27 | Bennett C. Frank | Antisense modulation of superoxide dismutase 1, soluble expression |
| JP2005508196A (ja) | 2001-11-07 | 2005-03-31 | アプレラ コーポレイション | 核酸分析の汎用ヌクレオチド |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
| JP2012504389A (ja) | 2008-09-22 | 2012-02-23 | ダイセルナ ファーマシューティカルズ， インコーポレイテッド | 修飾を有するｄｓＲＮＡによる遺伝子発現の特異的な阻害のための組成物および方法 |
| US8691971B2 (en) | 2008-09-23 | 2014-04-08 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| AU2009336191B2 (en) | 2008-12-18 | 2017-08-24 | Novo Nordisk A/S | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| US8999950B2 (en) * | 2011-10-05 | 2015-04-07 | Protiva Biotherapeutics Inc. | Compositions and methods for silencing aldehyde dehydrogenase |
| JP2015501155A (ja) | 2011-10-25 | 2015-01-15 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ｇｃｃｒ発現のアンチセンス調整 |
| EP2928877B1 (en) | 2012-12-06 | 2020-01-22 | Merck Sharp & Dohme Corp. | Disulfide masked prodrug compositions and methods |
| JP2017522046A (ja) | 2014-06-06 | 2017-08-10 | ソルスティス バイオロジクス，リミティッド | 生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物 |
| JP7105065B2 (ja) * | 2014-12-15 | 2022-07-22 | ダイセルナ ファーマシューティカルズ， インコーポレイテッド | リガンド修飾二本鎖核酸 |
| JP7249080B2 (ja) | 2016-08-23 | 2023-03-30 | ディセルナ ファーマシューティカルズ インコーポレイテッド | 可逆的に修飾されたオリゴヌクレオチドを含む組成物及びその使用 |
| KR102350647B1 (ko) | 2016-09-02 | 2022-01-14 | 다이서나 파마수이티컬, 인크. | 4'-포스페이트 유사체 및 이를 포함하는 올리고뉴클레오타이드 |
| WO2018094116A1 (en) * | 2016-11-17 | 2018-05-24 | Retrotope, Inc. | Isotopically modified components and therapeutic uses thereof |
| JP7155239B2 (ja) * | 2017-04-05 | 2022-10-18 | サイレンス・セラピューティクス・ゲーエムベーハー | 産物及び組成物 |
| EP4029942A1 (en) * | 2017-04-05 | 2022-07-20 | Silence Therapeutics GmbH | Products and compositions |
| CA3118327A1 (en) * | 2017-11-13 | 2019-05-16 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of aldh2 in a cell |
| MX2020004897A (es) * | 2017-11-13 | 2020-10-05 | Silence Therapeutics Gmbh | Acidos nucleicos para inhibir la expresion de lpa en una celula. |
| WO2019143621A1 (en) * | 2018-01-16 | 2019-07-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting aldh2 expression |
-
2020
- 2020-04-03 CA CA3135402A patent/CA3135402A1/en active Pending
- 2020-04-03 CN CN202080031480.1A patent/CN113748208A/zh active Pending
- 2020-04-03 KR KR1020217035578A patent/KR20210148264A/ko not_active Ceased
- 2020-04-03 JP JP2021559265A patent/JP2022526419A/ja not_active Abandoned
- 2020-04-03 WO PCT/US2020/026717 patent/WO2020206350A1/en not_active Ceased
- 2020-04-03 US US17/594,094 patent/US20220170025A1/en not_active Abandoned
- 2020-04-03 SG SG11202110896WA patent/SG11202110896WA/en unknown
- 2020-04-03 AU AU2020252560A patent/AU2020252560A1/en not_active Abandoned
- 2020-04-03 EP EP20723627.4A patent/EP3947683A1/en not_active Withdrawn
- 2020-04-03 MX MX2021012126A patent/MX2021012126A/es unknown
- 2020-04-03 BR BR112021019793A patent/BR112021019793A2/pt not_active IP Right Cessation
-
2021
- 2021-09-30 IL IL286868A patent/IL286868A/en unknown
- 2021-10-04 CL CL2021002585A patent/CL2021002585A1/es unknown